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Abstract
Therapeutic hypothermia has consistently been shown to be a robust neuroprotectant in many labs 
studying different models of neurological disease Although this therapy has shown great promise, 
there are still challenges at the clinical level that limit the ability to apply this routinely to each 
pathological condition. In order to overcome issues involved in hypothermia therapy, 
understanding of this attractive therapy is needed. We review methodological concerns 
surrounding therapeutic hypothermia, introduce the current status of therapeutic cooling in various 
acute brain insults, and review the literature surrounding the many underlying molecular 
mechanisms of hypothermic neuroprotection. Because recent work has shown that body 
temperature can be safely lowered using pharmacological approaches, this method may be an 
especially attractive option for many clinical applications. Since hypothermia can affect multiple 
aspects of brain pathophysiology, therapeutic hypothermia also could be viewed as a model of 
neuroprotection, which could be used to identify potential therapeutic targets. We discuss how 
research in this area carries the potential to improve outcome from a variety of neurological 
conditions such as hypoxia, ischemia, trauma and hemorrhage.
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1. INTRODUCTION
Based on promising results from numerous experimental studies from multiple different 
laboratories, hypothermia has been viewed as an attractive therapy for several acute 
neurological diseases. Therapeutic hypothermia (TH) has been extensively studied at the 
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experimental level, and has shown benefit against a variety mechanisms of brain injury, 
including reduction in metabolic activity, glutamate release, inflammation, production of 
reactive oxygen species, and mitochondrial cytochrome c release [1,2]. In various 
experimental models of acute brain diseases, several laboratories have consistently 
demonstrated that hypothermia ameliorates the extent of brain injuries and improves 
neurologic function. Based on past experimental research, recent clinical studies have 
established that therapeutic cooling improves neurological outcome from various acute brain 
insults, including global ischemia after cardiac arrest [3,4], and neonatal hypoxia-ischemia 
[5–7]. For other acute cerebral insults, such as ischemic stroke [8,9] and traumatic brain 
injury [10,11], the beneficial effect in clinical settings is now under investigation [12–15], 
and its strong neuroprotective effect has been shown consistently by several laboratories in 
preclinical models [16–18].
We reviewed optimal conditions for hypothermic therapy, in terms of target temperature, 
therapeutic duration, and attaining target temperature. In addition, we will discuss cellular 
and molecular pathways which are influenced by cooling. Since TH has been shown in the 
laboratory to have a robust and multifaceted neuroprotective effect, this therapy could be 
viewed as a model of neuroprotection. Precise understanding of this therapy may aditionally 
be helpful in the development of novel therapeutics. Papers cited in this article were 
identified using PubMed, and papers were selected which were considered to be 
scientifically reliable, important, and current.
1. OPTIMAL CONDITION FOR THERAPEUTIC HYPOTHERMIA
Therapeutic hypothermia is defined as an intentionally induced, controlled reduction from a 
normal body temperature of 37~38°C. Generally, classifications differentiate hypothermia 
into mild (32~35°C), moderate (28~32°C), deep (20~28°C), and profound (≤20°C). In early 
studies, deep states of hypothermia were commonly used. However, because of numerous 
complications and difficulty in achieving and maintaining these temperatures, mild to 
moderate hypothermia have become more attractive alternatives [19]. In a meta-analysis of 
animal studies, the benefits of hypothermia were inversely related to the temperature 
attained. Hypothermia also reduced infarct size by >40% with temperatures of 34°C or 
below [16]. However, specific studies that directly compared different temperatures failed to 
show dose dependent neuroprotection comparing temperatures of 27°C vs 32°C [20] and 
30°C vs 33°C [21].
This dose non-dependency may be explained by the detrimental effects of cooling itself, or 
by a lack of statistical power from the experimental models used. That is, experimental 
studies may not have had the statistical power to detect small differences in outcomes, 
compared to the larger differences seen with the normothermic control. Nevertheless, the 
optimal target temperature should be determined so as to maximize its beneficial effect and 
minimize any detrimental effect. In clinical settings, the current literature suggests that 
cooling to 32~34°C may be optimal .
Numerous laboratory studies have attempted to determine the optimal timing of cooling. 
Early initiation of cooling prior to brain injury seems to confer the most positive outcome, 
but this is generally not feasible in many clinical settings. In a prior review of ischemic 
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stroke models [17,22], it was reported that reduction of infarct size is commonly observed 
when cooling is begun within 60 to 180 minutes of onset. In contrast, in models of global 
cerebral ischemia, neuroprotection was observed, even when hypothermia was initiated 6 
hours after ischemia onset [23,24]. Thus, there is significant variation in the therapeutic time 
window depending on the type of brain injury.
The optimal duration of therapeutic hypothermia is also not well known. Some groups have 
used brief durations of hypothermia (0.5~5 hours), whereas others used longer periods 
(12~48 hours). In a few studies of ischemic stroke where the duration of hypothermia 
therapy was compared directly, durations of 1–3 hours appeared effective, whereas durations 
between 30 min to 1 hour were not [21,25]. In global cerebral ischemia, intra-ischemic 
hypothermia (rectal temperature 28~32°C) completely prevented hippocampal cell damage 
if continued for 4 or 6 hours, whereas 2 hours of hypothermia protected less well, and 1 hour 
or less did not protect at all [26]. Longer cooling durations may be necessary especially 
when the initiation of cooling is delayed. Previous reports have shown that prolonged 
hypothermia initiated 4~6 hours after ischemia and maintained for 24 hours can provide 
sustained functional and histological neuroprotection as far as 6 months onset [27]. These 
data indicate that prolonged cooling can provide neuroprotection when treatment initiation is 
delayed by a few hours [28].
2. Hypothermia therapy and pharmacological approaches
2.1. Pharmacological Induction of Hypothermia—There has been a recent surge of 
interest in the investigation of drug-induced hypothermia as a treatment option for acute 
brain injuries [29]. This approach has been proposed for the aim of maximizing the 
beneficial effect of hypothermia in clinical settings with less adverse reactions. Currently, 
there are eight classes of pharmacological agents which are capable of inducing hypothermia 
(Table 1). These agents are capable of affecting a multitude of systems including 
cannabinoid (CB), opioid, transient receptor potential vanilloid 1 (TRPV1), neurotensin, and 
thyroxine derivatives, dopamine, gas, and adenosine derivatives. Interestingly, some of these 
drugs such as those in the cannabinoid families, may not only provide neuroprotection 
through hypothermia induction but may provide neuroprotection through other mechanisms 
as well [29]. One study used a CB1 receptor agonist (WIN55212–2) and demonstrated that a 
low dose (1mg/kg), which does not decrease body temperature, can exert a neuroprotective 
effect in a murine stroke model [30]. Further, keeping temperature between 37 and 38°C, the 
CB1 receptor agonist did not abolish its neuroprotective effect [31]. This neuroprotective 
effect of the CB system may be due to reduced excitotoxicity via reduced glutamate 
release[32]. In addition, the CB1 receptor agonist can reduce inflammation and microglial 
activation as well as reduce BBB disruption after ischemic injury [33]. These 
neuroprotective effects in addition to lowering body temperature may suggest additional 
benefits due to synergistic effects[1].
Another advantage of pharmacologically induced hypothermia is its effect on central 
thermoregulation at the level of the hypothalamus [29]. Several drugs, such as TPRV1 
receptor, neurotensin and thyroxine families, have been shown to have effects on 
thermoregulatory control by decreasing the compensatory hypothermic response during 
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cooling. This effect on thermoregulation could also reduce shivering and vasoconstriction, 
which often interferes with the therapeutic effect of hypothermia. Therefore, these agents 
might be efficacious in combination with physical hypothermia in reducing discomfort, 
hastening the cooling process, and prolonging tolerable cooling durations [29].
2.2. Synergistic effects of several neuroprotectants and Hypothermia 
therapy—Some drugs have been reported to provide synergistic neuroprotective effects 
when combined with hypothermia treatment (Summarized in Table 2) [34]. One such drug 
reported recently is glibenclamide (GBC), a sulfonyl urea receptor 1-transient receptor 
potential M4 (SUR1-TRPM4) channel inhibitor, which is already used as an antidiabetic 
drug [35–37]. Zhu et al. [35] revealed that the combination of GBC and TH exhibited 
synergistic effects in a rodent stroke model. Combination treatment was associated with 
greater reductions in brain edema, better neurological recovery, prevention of tight junction 
protein loss, and enhanced anti-inflammatory effects. Furthermore, in cardiac arrest model, 
combined therapy with GBC and HT also showed trends towards less histological injury 
[37].
Historically, this synergistic neuroprotection was first reported with MK801, which is 
antagonist of the NMDA receptor [38–40] . Several drugs have since been reported to 
possess neuroprotective effects in various acute brain injury models have been tested for 
synergistic effects when combined with TH. Reducing excitotoxicity with NMDA 
antagonists is one such approach. Synergistic effects of MK801 [38–40] , Selfotel 
(CGS-19755) [41,42] and magnesium ion (Mg2+) [43,44] were tested in combination with 
TH. Although MK801 did not show enhanced neuroprotective effects in some laboratories 
[38,39], Mg2+, and other NMDA receptor antagonists did [44]. In contrast, another study of 
stroke using a model of permanent MCAO failed to find a benefit with the combination of 
Mg2+ and TH[45]. Reasons for these discrepancies are not fully clear, but could be 
explained by differences in the models used, and other experimental factors such as when 
therapy was initiated, how long treatment continued, and the depth of cooling.
Diverse neuroprotective strategies in combination with hypothermia has also been 
investigated (Table 2). Anti-inflammatory strategies have been studied in in combination 
with hypothermia. FK506 (Tacrolimus) [46] and minocycline are representative drugs which 
have shown synergy with TH. Combining FK506 with hypothermia prolonged its 
therapeutic time window and led to decreased brain damage (lesion volume) than either 
treatment alone[46]. Another anti-inflammatory drug is minocycline, a second-generation, 
semi-synthetic, tetracycline, which possess inhibitory effects on inducible nitric oxide 
synthase (iNOS) and matrix metalloproteinase (MMPs)[47]. One study involving ischemic 
stroke model found a small, albeit non-significant, increase in therapeutic benefit when 
minocycline was combined with hypothermia relative to either treatment its own [48]. 
Another attractive strategy is reduction of oxidative stress. Edaravone (3-methyl-1-phenyl-2-
pyrazolin-5-one) can scavenge excess free radicals. A previous report found that the 
combination of edaravone and hypothermia can reduce the damage in an ischemic stroke 
model, although hypothermia itself failed to show a significant beneficial effect [49].
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While these compounds and strategies seem feasible for clinical translation, there are no 
reports that have proven their benefit in humans so far. Further research in both pre-clinical 
and clinical trials are still needed to clarify how such approaches could be applied.
3. THERAPEUTIC HYPOTHERMIA IN VARIOUS ACUTE BRAIN DISEASES
Current standpoint of hypothermia in each acute brain diseases are summarized in Table3.
3.1 Hypothermia for Cardiac Arrest—Several experimental studies have 
demonstrated the neuroprotective effects of mild or moderate hypothermia for cardiac arrest 
(global ischemia) [17,19]. These studies have shown the durability of this protective effect 
and have defined a temporal therapeutic window which can be lengthened provided cooling 
is prolonged [50]. Several studies in global cerebral ischemia models have found that 
cooling in the range of 30~34oC consistently leads to robust neuroprotection. Mild 
hypothermia for 12 h enhances neuroprotection of hippocampal CA1 after a 3 min insult in a 
global cerebral ischemia model in gerbils, whereas neuroprotection following a 5 min insult 
required cooling for 24 h [24]. Thus, longer cooling periods may be more suitable for more 
severe insults.
The clinical benefit of hypothermia has also been demonstrated in two large-scale clinical 
studies based on data from multiple medical centers conducted in 2002 [3,4]. These clinical 
studies showed that mild hypothermia for 12~24h reduces mortality and improves functional 
recovery from cardiac attest [3,4]. Cooled patients had improved neurological outcome 6 
months later, compared to those who were maintained at normal body temperature [4]. Since 
then, therapeutic cooling has been widely accepted as standard treatment for comatose 
survivors of cardiac arrest.
3.2 Hypothermia for neonatal hypoxic-ischemic encephalopathy (HIE)—
Therapeutic hypothermia has also been shown to be effective in preventing perinatal brain 
injury from hypoxic-ischemic encephalopathy (HIE) [51]. There have been several clinical 
trials of newborns with HIE [5,7]. These studies have shown benefit in infants with moderate 
and severe HIE; however, long term, lifelong benefits are especially key in pediatric 
populations, and there are no reports of outcomes beyond 21 months of age. This condition 
has also been studied in the laboratory, although not as extensively as in adult models.
3.3 Hypothermia for Ischemic Stroke—In abundant experimental studies of 
experimental stroke (focal cerebral ischemia models), mild or moderate hypothermia has 
shown to be neuroprotective and improves neurological function when cooling was initiated 
within a few hours of ischemia onset. There is no doubt that hypothermia reduces infarct 
volume and improves neurological function in the range of 24°C to 33°C after onset in 
ischemic stroke models [17,22].
Recently, many experimental studies and large clinical trials demonstrated that 
recanalization of occluded vessels within specific time windows after ischemia 
(recanalization therapy) increases the likelihood of a good outcome [17]. In transient middle 
cerebral occlusion (tMCAO) models, hypothermia consistently showed neuroprotection, 
whereas the results of permanent MCAO (pMCAO) were conflicting. Thus, the role of 
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therapeutic hypothermia in combination with recanalization therapy in clinical setting 
becomes very important [19].
As TH was shown to be neuroprotective in both cardiac arrest patients and neonatal HIE 
patients, there is hope that it will similarly reduce morbidity and mortality following 
ischemic stroke. Indeed, a few preclinical studies showed that mild therapeutic hypothermia 
initiated during acute ischemic stroke or after a short delay reduced infarct size and 
mitigated functional impairment in a recent meta-analysis [16,52]. In addition to these 
studies, another study showed feasibility and tolerability, and established regimens to 
prevent or reduce shivering in the typically awake stroke patient [9,53]. In a recent 
multicenter study, an endovascular cooling device was used in combination with the 
administration of recombinant tissue plasminogen activator (rt-PA) in acute stroke patients. 
Here, patients could be treated within 0–6 h of symptom onset followed by endovascular 
cooling to 33oC for 24 h. While the study was not designed to evaluate relative efficacy of 
TH, this regimen appeared well tolerated, although there was increased incidence of 
pneumonia amongst cooled patients [54]. However, these studies were all small, and larger 
prospective studies have yet to be published. A few clinical trials in ischemic stroke [14,15] 
showed promising effects by TH. These results may provide useful direction in the design of 
future clinical trials.
3.4 Hypothermia for Intracerebral Hemorrhage—Intracerebral hemorrhage (ICH) 
is a devastating stroke that can occur in patients with high blood pressure. The mortality and 
morbidity from ICH is often higher than ischemic stroke, and there is currently no specific 
therapy with proven benefits for this condition. Recent experimental studies have been 
directed at determining the pathophysiology of ICH and at identifying effective treatments, 
including the study of TH. In experimental reports, a few studies have shown that 
hypothermia reduced brain edema, inflammation, and blood-brain barrier (BBB) disruption 
in ICH models created by intra-striatal thrombin (to model edema associated with ICH) [55] 
or autologous whole blood [56–58] injection. However, this was not as consistent a finding 
across labs. In fact, some labs have observed that histological and functional benefits are not 
consistently found [57] and one report described increased bleeding in the brains of cooled 
animals [58]. Although this appears to depend upon the model, insult severity, and time of 
treatment, in another study, delayed mild hypothermia (48 h) after ICH failed to reduce 
lesion size when started soon after collagenase-induced ICH, whereas treatment delayed 12 
h still showed neuroprotection [58]. In a recent meta-analysis of preclinical studies of TH in 
ICH [59], authors concluded that hypothermia can reduce edema, protect blood-brain barrier 
disruption, and can improve behavioral outcomes. However, one study found increased 
bleeding with early cooling, and some protection was observed only when cooling was 
delayed 12h [60]. The authors pointed out that hypothermia could affect critical pro-
coagulant and thrombolytic systems, and predispose to bleeding in the acute period. The 
authors also suggested that it is also possible that hypothermia exacerbated complications of 
the initial increased blood pressure observed in these models. These findings indicate that 
further studies are needed to clarify the reasons for worsening in certain scenarios, and 
whether cooling might be detrimental if not applied in an optimal manner.
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At the clinical level, application of therapeutic hypothermia in patients with ICH remains 
controversial [61]. Kollmar et al. [62] reported that 12 patients with large ICH were treated 
with hypothermia to 35°C for 10 days (initiated 3–12 h after symptoms onset) and these 
patients were compared to data from a local hemorrhage data bank. In the hypothermia 
group, edema volume remained stable during 14 days, whereas edema significantly 
increased in the control group. A recent systematic review and meta-analysis [61] revealed 
that hypothermia can reduce the incidence of delayed cerebral ischemia, although TH did 
not show significant differences in mortality and poor outcomes. Furthermore, on-going 
clinical trials Targeted temperature management after intracerebral hemorrhage (TTM-ICH) 
and Cooling in intracerebral hemorrhage (CINCH))explore the safety and efficacy of 
hypothermia in ICH patients [63,64].
3.5 Hypothermia for Subarachnoid hemorrhage—Subarachnoid hemorrhage 
(SAH) is often due to aneurysmal rupture, and hypothermia is occasionally used 
intraoperatively during aneurysm repair. There are several animal model studies of SAH that 
hypothermia exhibited neuroprotection. In one study, mild hypothermia applied for 2h led to 
improved post-hemorrhagic neurological deficits, reduced intracranial pressure and 
postoperative weight gain by 1–7 days if cooling was delayed for 3 h after SAH [65]. 
Another study demonstrated the neuroprotective effects of hypothermia on the acute changes 
after experimental SAH as evaluated by diffusion weighted MRI (DWI) and magnetic 
resonance spectroscopy (MRS) [66]. The investigators established that hypothermia 
improved early development of cytotoxic edema, lactate accumulation, and a general 
metabolic stress response after SAH a rat model. The mechanisms underlying this protective 
effect have not been explored as extensively as in brain ischemia models, but one study 
showed that hypothermia interrupted the early expression of genes associated with cellular 
stress, such as c-jun and Hsp 70 [67].
At the clinical level, Muroi and colleagues [68] assessed the neuroprotective effects of TH in 
combination with high-dose barbiturates. The inflammatory response in 7 patients with this 
intervention showed decreased systemic and cerebrospinal fluid levels of interleukin 
(IL)-1β, IL-6, and leukocyte counts compared to a group of 8 patients who received no 
intervention. Interestingly, while cooling suppressed most immune markers, cooling 
increased tumor necrosis factor alpha (TNF-α) [68]. In a large multi-center randomized 
study, mild intra-operative hypothermia during surgery for intracranial aneurysms failed to 
improve neurologic outcomes among favorable-grade patients with aneurysmal SAH 
(WFNS grade 1–3) [69]. In response to these results, more studies have focused on 
therapeutic hypothermia for patients with poor grade SAH. One clinical study conducted by 
Seule and colleagues [70] evaluated the feasibility and safety of mild hypothermia in 
patients with poor grade aneurysmal SAH who experience intracranial hypertension and/or 
cerebral vasospasm [70]. The findings led authors to conclude that prolonged systemic 
hypothermia may be considered a last-resort option for a carefully selected group of younger 
SAH patients with resistant intracranial hypertension or cerebral vasospasm. Thus, the 
clinical effectiveness of therapeutic cooling for SAH remains unclear. This may be due to 
many factors including fever, vasospasm, surgical technique, and excessive decompression 
by skull removal, that may affect outcomes in patients with SAH.
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3.6 Hypothermia for traumatic brain injury—Traumatic brain injury (TBI) is the 
primary cause of significant morbidity and mortality in young populations. Similar to 
hypoxic and ischemic injury, it is known that TBI leads to a spectrum of secondary injury 
through ionic fluxes, excitotoxicity, necrotic and apoptotic cell death and inflammation 
[71,72]. Cell damage is not only produced by the trauma itself, but by a series of these 
pathophysiological mechanisms which may cause secondary injury. Because numerous 
preclinical studies have shown that cooling affects multiple pathological pathways, the use 
of TH has been tested in a variety of preclinical and clinical situations [2,71].
In the area of pre-clinical TBI research, Clifton et al. [73] first reported that mild 
hypothermia following a lateral fluid percussion brain injury in rats improved motor 
recovery. Subsequent preclinical studies using similar or different TBI models resulting in 
both focal and diffuse injury also demonstrated that early (within 5 minutes) posttraumatic 
hypothermia using systemic cooling strategies could reduce contusion volume and protect 
against patterns of neuronal vulnerability [74,75]. In addition, TH also attenuated the 
severity of diffuse axonal injury (DAI) and blood brain barrier (BBB) damage [76,77] 
Furthermore, recent studies revealed that TH can improve not only acute but also chronic 
behavioral outcome measures including sensorimotor and cognitive function [78].
Based on promising preclinical findings, several clinical trials had been carried out to test its 
efficacy in TBI patients. In 1997, Marion et al. [79] published a randomized study involving 
84 patients with severe TBI who were treated using mild hypothermia (33°C for 24 h). There 
was a significantly better neurologic recovery at 3 and 6 months among the patients with 
GCS scores of 5–7 at the time of admission to the hospital [79]. Jian et al. [80] also reported 
the results from a randomized study of 215 patients with TBI which showed that prolonged 
hypothermia (5 days) is effective in improving neurological outcomes. In contrast, several 
randomized control studies showed no benefit on neurological outcome in severe TBI 
patients [81,82]. Although the efficacy of hypothermia in TBI is still controversial, several 
hypothermia trials in TBI have been carried out [83,84]. The European Study of Therapeutic 
Hypothermia Trial, an international multicenter randomized control trial examined the effect 
of titrated therapeutic hypothermia on intracranial pressure and neurological outcome. 
Recently, the trial carried out among 387 patients at 47 centers in 18 countries have been 
completed. The study reported that TH, while successfully reducing intracranial pressure, 
did not ultimately improve functional recovery [85,86]. Collectively, results from both pre-
clinical and clinical studies of TH in TBI continues to evolve, and a number of factors 
including patient selection and the timing of the therapy appear to be critical in successful 
trial design.
3.7. Hypothermia for spinal cord injury—As well as other acute neurological 
diseases, spinal cord injury (SCI) may also benefit from TH[87,88]. Damage and pathology 
related to SCI are categorized into 2 phases: primary and secondary. Similar to related 
conditions, hypothermia for SCI focused on mitigating the secondary phase of damage, with 
the goal of preventing further damage and improving neurological outcomes.
Based on numerous experimental reports, there have been a wide range of reported 
histologic, biochemical, and pathophysiologic beneficial effects attributed to 
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hypothermia[88]. These include reduction in level of excitotoxic metabolite glutamate in the 
cerebrospinal fluid[89], reduced vasogenic edema at the site of injury[90,91], decreased 
neutrophil invasion[92], and lack of reduction of blood flow after SCI[93] There is also 
evidence that hypothermia decreases tissue metabolism and energy requirements[94], 
oxidative stress[95], and reduces tissue hemorrhage[90,91] and apoptosis[96]. However, in 
clinical settings, the benefit of hypothermia in SCI is also still controversial [87,88]. 
Considering that SCI is a devastating injury with uncertain therapeutic options, except 
possibly acute methylprednisolone, large and well-designed prospective study are still 
lacking.
4. MECHANISMS OF HYPOTHERMIC NEUROPROTECTION
4.1 Acute Molecular Events
4.1. Cellular Metabolism: The neuroprotective effect of hypothermia has long been 
linked to decreases in metabolic rate and the reduction of cerebral blood flow [25,26]. 
Hypothermia decreases the brain metabolic rates of oxygen consumption and glucose 
metabolism [26]. Hypothermia, on average, decreases brain oxygen consumption by 
approximately 5%/°C fall in body temperature in the range of 22–37°C [26,97], and in 
anesthetized animals, oxygen consumption reduces linearly between 37 and 38°C [98]. 
Hypothermia can interrupt downstream consequences of increased lactate production due to 
dependence on anaerobic metabolism and the development of acidosis by preserving the 
brain’s metabolic stores [2]. Hypothermia conserves high-energy phosphate compounds, 
such as adenosine triphosphate (ATP), and maintains tissue pH, all mechanisms likely linked 
to its suppressive effect on brain metabolism, which conserves tissue ATP levels. ATP is 
needed to maintain ion gradients, and when these concentration gradients are disturbed, such 
as in the case of ischemic stroke, calcium influx occurs and leads to increased extracellular 
glutamate levels [27]. Several investigators also demonstrated that hypothermia also 
significantly decreases the release of excitotoxins and calcium influx due to cerebral 
ischemia [99,100]. The glutamate receptor 2 (GluR2) subunit of the α-smino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid (AMPA) receptor is thought to be responsible for limiting 
calcium influx. GluR2 suppression by ischemia is thought to lead to massive calcium entry 
which, in turn, activates neuronal cell death by activating numerous injurious processes such 
as proteases and lipases. In fact, some investigators have hypothesized that one potentially 
neuroprotective mechanism of hypothermia is that it could salvage neurons from delayed 
calcium influx via GluR 2 receptors [101]. In recent work, our group has established that 
hypothermia decreases ischemia-induced upregulation of calcium influx through a newly 
characterized calcium sensing receptor (CaSR) [102]. CaSR is thought to sense changes in 
extracellular calcium levels, but also appears to reciprocally down regulate GABA receptors, 
thereby decreasing inhibitory tone. Cerebral ischemia increases expression of CaSR while 
inhibiting GABA-B-R1 expression, but this is reversed by TH [102]. Thus, TH may have 
identified CaSR as a potential target for treatment of stroke and related conditions. 
Excitotoxic neurotransmitters are released early after ischemia onset, and it is well known 
that glutamate antagonists have a rather narrow temporal therapeutic window of 1–2 h. Since 
earlier cooling is superior to delayed cooling, this may explain some of the protective effect 
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of hypothermia. However, cooling even after glutamate release has occurred is still 
protective [103].
4.2. Early Molecular Events: Hypothermia has also been shown to affect other acute 
processes associated with ischemia, including the induction of immediate early gene 
expression [104] and the cellular stress response [105]. Some reports showed that one of the 
stress related proteins, the 70kDa inducible heat shock protein (HSP70), is increased under 
hypothermic conditions [106], and this might be consistent with HSP70’s neuroprotective 
properties [105]. However, it is still unclear whether hypothermic neuroprotection is 
necessarily mediated through alterations in immediate early gene expression and the cellular 
stress response [2].
Micro RNAs (miRNAs), a subset of non-coding RNAs, have been a topic of recent 
investigation in brain injury models, where their expression has been observed to increase as 
early as 2h after onset. It is conceivable that they have an important role in pathogenesis of 
acute brain injury, and the roles of specific miRNAs are currently under investigation. A 
report in traumatic brain injury models showed that therapeutic hypothermia alters the 
expression of several miRNAs, as represented by miR-874 and miR-451. In particular, a few 
miRNAs, including miR-874 and miR-451 were most changed by cooling, with both being 
decreased by cooling at 7h, while miR-451 was increased by cooling at 24h compared to 
normothermia[107]. Further research is needed to better define their role in brain injury.
Cold-inducible (or ‘cold shock’) proteins are also of relevance to hypothermic 
neuroprotection [2]. Two of these genes, cold-inducible RNA-binding protein (CIRBP) and 
RNA binding motif protein 3 (RBM3), have been reported to be specifically induced by 
therapeutic hypothermia [2,108]. CIRBP has been speculated to protect and restore native 
RNA conformation during stress, and protects against apoptosis by upregulating ERK. 
RBM3 may also protect cells from death pathway by acting in a manner similar to X-linked 
inhibitor of apoptosis (XIAP) [109]. A few studies have begun to explore their significance 
in neuroprotection and potential mechanisms of protection by hypothermia. For instance, 
CIRBP mRNA was increased in rodent stroke models, with even higher increases in animal 
exposed to hypothermia [110]. RBM3 was also upregulated by hypothermia in neuronal 
cells, and hypothermia’s neuroprotective effect was eliminated when RBM3 expression was 
inhibited. [111]
4.3 Sub-acute Molecular Events
4.3.1 Apoptosis: In past studies of acute brain injury models, hypothermia was shown to 
prevent damage by interrupting both the intrinsic and extrinsic apoptotic pathways. The 
intrinsic pathway takes place within the cell at the level of the mitochondria [112], while the 
extrinsic pathway is triggered by engagement of a cell surface receptor by its ligand(s) [113]. 
Hypothermia can interrupt these pathways, but whether cooling has any effect on neuron 
survival depends on whether apoptosis actually occurs in a given model or paradigm. In 
models of global cerebral ischemia, hypothermia can interfere with changing the expression 
of Bcl2 family members. Some Bcl2 family members are pro-apoptotic, while others are 
anti-apoptotic. Thus, the relative balance of Bcl2 proteins could determine the cell’s fate. A 
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few studies in hypothermia models have shown that cooling leads to suppression of pro-
apoptotic Bax while increasing anti-apoptotic Bcl2 [114–117], reducing cytochrome c 
release [114,118]and decreasing caspase activation [119,120]. Delta-PKC (a protein kinase 
C isoform) has been shown to contribute to ischemic injury by inhibiting phosphorylation 
and thereby activation of pro-survival kinase Akt and facilitating cytosolic translocation of 
pro-apoptotic BAD [121]. Caspase-3 leads to transport of delta-PKC from the cytosol to the 
mitochondria and nucleus, where it interacts with other molecules to induce apoptosis [122]. 
In contrast, a different PKC isoform, epsilon-PKC is anti-apoptotic, and is degraded by 
caspases. While hypothermia did not appear to alter overall levels of delta-PKC [123], it 
blocked its translocation to the mitochondria and the nucleus and stimulated epsilon-PKC in 
brain ischemia models [124].
Extrinsic apoptotic pathways also appear to be involved in various acute brain injuries. The 
most widely studied apoptosis-inducing receptor and ligand pair are Fas and FasL, 
respectively. How FasL binds Fas is somewhat unclear, as many reports indicate that FasL 
must be present on the cell’s surface in order to engage Fas, but other reports indicate that 
FasL must first be cleaved from the surface by activated matrix metalloproteinases (MMPs) 
and solubilized prior to any interaction with Fas. Hypothermia seems to prevent FasL 
cleavage, as levels of soluble FasL are decreased in ischemic rodent brains exposed to TH, 
as are levels of several MMPs [125,126]. Decreased soluble FasL levels was also associated 
with decreased caspase 8 activation, an event which occurs downstream of Fas activation 
[127]. A recent study [128] used an experimental stroke model that showed that TH inhibits 
Fas trafficking through downregulation of dynamin, a guanine triphosphatase thought to 
transport Fas from the ER to the cell surface. This may suggest a novel therapeutic target in 
stroke as well as other acute neurological diseases. In models of severe ischemic stroke 
(MCAO of 2 hours or longer), hypothermia does not appear to affect Bcl-2 family members 
or caspase activation, but does prevent cytochrome c release [118]. These observations might 
be explained by yet a third apoptotic pathway which involves direct cell killing by 
mitochondrial AIF (apoptosis inducing factor) release, and is caspase independent [129]. 
Hypothermia was shown to reduce apoptotic cell death in a more severe model of ischemic 
stroke while suppressing AIF translocation [130].
Laboratory studies have also investigated other molecules implicated in apoptotic pathways 
which have been shown to be affected by hypothermia as well. Phosphatase and tensin 
homolog (PTEN) is a tumor suppressor molecule with pro-apoptotic functions. PTEN 
deletion has previously been shown to prevent brain injury [131]. However, PTEN 
phosphorylation leads to its deactivation, and is normally decreased in brain injury [132]. 
Under conditions of hypothermia where neuroprotection was observed, phosphorylated 
PTEN levels remained the same but reduced in non-neuroprotective conditions of 
hypothermia [123]. Thus, the deactivated form of this pro-apoptotic protein seems to 
correlate to hypothermic neuroprotection. The mechanisms underlying this correlation 
require further investigation.
4.3.2. Survival pathways: Interestingly, while hypothermia downregulates a majority of 
cell death pathways, it can also upregulate cell survival and growth pathways. Several 
neurotrophic factors in the brain have been reported with regard to their therapeutic potential 
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in acute brain injuries. These factors play a key role in multiple neuronal cell processes such 
as synaptic function and plasticity and sustain neuronal cell differentiation, survival, and 
morphology. In ischemic models, exogenous administration of one or more of these factors 
seemed to improve functional neurological outcome without necessarily affecting lesion 
size. Hypothermia increased the brain-derived neurotrophic factor (BDNF) after ischemic 
brain insults [133,134], glial-derived neurotrophic factor (GDNF) [135] and neurotrophin 
[136]. Hypothermia also activated extracellular signal-regulated kinase-1/2 (ERK1/2) 
phosphorylation, a downstream element of BDNF signaling [133]. In other cases, 
hypothermia has been reported to induce protective effects of ERK1/2 and to interrupt the 
activation of ERK1/2 and suppresses inflammation and cell death [137].
Studies on pro-survival protein Akt have been reported. Akt is a serine/threonine protein 
kinase that regulates proliferation, apoptosis, glucose metabolism, transcription and cell 
migration. After phosphorylation by phosphoinositol 3-kinase (PI3K), activated Akt 
phosphorylates (that is, inactivates) proapoptotic proteins such as glycogen synthase-3beta 
(GSK-3beta) and Bcl-xL/Bcl-2-associated death promoter (BAD). In an animal model of 
ischemic stroke, hypothermia appeared to promote activation of Akt while reducing infarct 
size. This effect disappeared when hypothermia was combined with an Akt inhibitor [138].
4.3.3. Inflammation: Inflammatory accompanies a variety of acute neurological insults. 
These insults which lead to neuronal cell damage include a complex series of biochemical 
and molecular mechanisms [139]. Dying or dead cells trigger activation of several immune 
responses via microglia, a monocyte lineage cell that resides in the brain, as well as 
infiltrating immune cells from the circulation [140,141]. Further, there is evidence that brain 
cells not normally viewed as immunologic, including astrocytes and even neurons, are 
capable of elaborating immune molecules. Several animal studies have now shown that 
inhibiting various aspects of this immune response by hypothermia may be involved in the 
beneficial effects on neurological outcome following brain injuries [142]. Following 
ischemic stroke, inflammation can be detected within a few hours after the injury onset. 
Because of the unanticipated nature of acute brain insults, the ensuing immune response is 
most likely innate, rather than adaptive. The innate immune response is a triggered by a 
variety of signals that, unlike the adaptive immune response, do not require antigen 
recognition. Mild and moderate hypothermia affect several pathways of the inflammatory 
response at different time points [132]. Microglia play an important role in this innate 
response [143]. At rest, microglia display a ramified appearance, but when activated, 
undergo a series of morphologic changes often leading to an amoeboid morphology making 
them phenotypically indistinguishable from circulating macrophages and monocytes. 
Microglial activation is the initial step in the brain inflammatory response. Depending on the 
stimulus, this step may be followed by infiltration of circulating monocytes, neutrophils, and 
T-cells, and by reactive astrocytosis [144]. Microglial activation occurs through a complex 
series of events, with changes in morphology and gene expression which vary depending on 
the type, severity, and duration of the stimulus [145]. Hypothermia appears to decrease 
tissue density and activation of microglia. This effect leads to about 54% reduction in 
microglial activation after 3 days [146]. However, some phagocytic properties of microglia 
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likely exerts beneficial effects in the long term [147]; thus, suppression of microglial 
function may not be ideal at later timepoints.
After ischemic stroke, endogenous immune stimulators are collectively referred to as 
damage-associated molecular patterns (DAMPs). DAMPs include hyaluronan, surfactant 
protein and uric acid. These substances bind to and stimulate microglia and other immune 
cells leading to the upregulation of many immune mediators by activating several pro-
inflammatory transcription factors, including nuclear factor kappa B (NF-kB) [148], hypoxia 
inducible factor 1 (HIF-1), interferon regulator factor 1 and signal transducer and activator 
of transcription 3 (STAT3) [149]. Studies have also shown that hypothermia may suppresses 
inflammation at the transcriptional level, as it has been shown to suppress transcription 
factors such as NF-kB [150], MAPK [137,151] and JAK/STAT [152].
Cytokines were originally described as mediators involved in regulating the innate and 
adaptive immune systems. Cytokines are quickly and extensively upregulated in the brain in 
a variety of disease states [141,153]. The most studied cytokines related to inflammation in 
acute brain injury are tumor necrosis factor-α (TNF-α), several of the interleukins (IL) and 
transforming growth factor (TGF)-β. Among these cytokines, mild hypothermia can reduce 
the expression levels of pro-inflammatory cytokine (IL-1β) and TNF-α [138,141]; however, 
hypothermia also suppressed anti-inflammatory cytokines such as IL-10 and TGF-beta 
[154], indicating that hypothermia does not always result in a purely anti-inflammatory 
outcome.
Oxidative and nitrosative stresses may play a central role in this inflammatory response. 
Reactive oxygen species (ROS) are produced by injured brain cells, presumably because 
their mitochondria are no longer able to neutralize these reactive species [155]. ROS are also 
released by inflammatory cells, presumably as host defense against invading pathogens. The 
increase in ROS can then trigger more immune responses by leading to pro-inflammatory 
transcription factor activation, activation of endogenous immune molecules and can damage 
adjacent viable tissue that surround the area of injury [156]. Thus, ROS can participate in a 
rather vicious cycle of immune response activation and direct cytotoxicity. Several studies 
have now shown that hypothermia attenuates free radical formation and thus provides 
protection [157,158]. Hypothermia, by preventing the generation of ROS, has been shown to 
inhibit all of these downstream processes including the prevention of cytochrome c release, 
downregulation of pro-apoptotic factors and the prevention of caspase activation [159]. 
Similarly, nitrosative stresses include the increase in nitric oxide (NO) via the different nitric 
oxide synthase (NOS) isoforms, particularly the inducible NOS (iNOS) that is primarily 
found in immune cells [160]. Further, the ROS superoxide and NO can combine to form 
peroxynitrite, which is a particularly reactive species that is genotoxic as well. In various 
experimental models, hypothermia significantly attenuates increases in NOS isoforms.
The Mitogen-Activated Protein Kinase (MAPK) pathway is another important enzyme 
system in affecting inflammation, in a cell-type dependent manner. While there is no 
consensus on the role of ERK after ischemia stroke, there is also no consensus on the effect 
of hypothermia on ERK. Studies have shown that hypothermia suppresses ERK signaling in 
activated cultured microglia [137], while in an experimental stroke model, hypothermia 
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activates ERK in brain endothelial cells. This latter finding seems to be associated with 
reduction of intercellular adhesion molecule-1 (ICAM-1) expression, which is one of many 
inflammatory genes regulated by the MAPK signaling pathway, and is one of a class of 
adhesion molecules involved in trafficking circulating inflammatory cells to the CNS [151].
In brief, the effect of hypothermia on inflammation is largely suppressive, and this anti-
inflammatory property might serve as a major mechanism of hypothermic neuroprotection. 
Studies in a model of brain inflammation where cell death does not occur showed similar 
suppress in the immune response by hypothermia, and suggests that inflammatory responses 
are quite temperature sensitive [161].
4.3.4. Blood-Brain Barrier and Edema: The disruption of blood-brain barrier (BBB) 
after acute brain insults promote the secondary injuries by edema formation and 
hemorrhage, which is caused by structural and functional impairment of basement 
membrane tight junction proteins, transport proteins, endothelial cells, astrocytes and 
neurons. Studies have shown that mild and moderate hypothermia protects the BBB 
disruption [162] and decreases edema formation [163] by attenuating loss of vascular 
basement proteins [164]. Matrix metalloproteinases (MMPs) are recognized to break down 
the extracellular matrix, and can lead to disruption of the BBB causing further infiltration of 
circulating immune cells, serum proteins and hemorrhage. Inactivated MMPs are normally 
found in the cytosol, but in pathologic states, they can be transported extracellularly where 
they are cleaved to an active form and degrade substrates of the extracellular matrix [141]. 
MMP-2, −3 and −9 have been described in cerebral ischemia, but MMP-9 appears to be 
expressed in traditional immune cells. Neutrophilic MMP-9 expression after stroke 
correlates with worse outcome [165], and studies of bone marrow chimeras suggests that 
MMP-9 derived from circulating leukocytes contributes significantly to its pathology [166]. 
Hypothermia reduces proteolytic activities of MMPs and consequent degradation of vascular 
basement membrane proteins [164] and degradation the extracellular matrix [163]. It also 
prevents the degradation of extracellular matrix proteins agrin and laminin, both targets of 
activated MMPs [164]. In addition to suppressing MMPs, hypothermia has been shown to 
increase expression of endogenous MMP inhibitors, such as tissue inhibitor of 
metalloproteinase-2 (TIMP-2) [126].
BBB disruption increases brain edema through breakdown of the brain’s water balance. A 
water channel family, the aquaporins, facilitates water flux through the plasma membrane of 
many cell types. In rodent brain, several studies have demonstrated the presence of different 
types of aquaporins. Among these aquaporins, aquaprin-4 (AQP4) is the predominant 
subtype in the CNS microvasculature, and is present on astrocytic end-feet in contact with 
brain vessels. AQP4 expression is increased in reactive astrocytes in cerebral lesions 
[115,167], and its deficiency has been shown to reduce brain edema [168]. Mild 
hypothermia also reduces brain edema by suppressing AQP4 expression in models of 
intracerebral hemorrhage [56] and cardiac arrest [169]. In brief, by preserving structural 
proteins and cells constituting the BBB, and inhibiting the activation of damaging proteases 
and preventing the opening of water channels, hypothermia prevents secondary brain injury 
from brain edema and hemorrhage.
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In addition to water channel regulation, hypothermia also has been shown to affect 
molecular transport across the BBB. One study demonstrated that hypothermia decreased 
multi-drug resistance protein-1 (MDR-1) mediated transport but did not show any effect on 
passive diffusion and paracellular transport [2]. MDR-1 is a type of transport protein that 
mobilizes drugs and metabolites through transcellular pathways. The finding that 
hypothermia can affect drug transport points to a need for further pharmacokinetic studies 
under hypothermic conditions, since transport of drugs may be impacted by cooling. In 
particular, drugs that may be co-administered during cooling should be studied for any 
temperature dependent changes in pharmacokinetics.
4.4 Late Phase Molecular Events—Studies investigating the long-term impact of 
hypothermia include observations made weeks to months post cooling, well after cooling 
has ceased. Studies addressing hypothermia’s lasting effects has specifically examined on-
going recovery and repair mechanisms particularly in focal cerebral ischemia and traumatic 
brain injury models [170]. Though research has yet to reach a consensus on the matter, 
studies have identified correlations between therapeutic hypothermia and the injured brain’s 
regenerative capacity, stem-cell retention, neuronal synaptic connectivity repair, and 
neurogenesis as well as gliogenesis and angiogenesis.
Neurons in the injured brain are known to change morphology and lose synaptic 
connectivity as they undergo cell death [171]. In parallel, endogenous recovery mechanisms 
are also activated after injury, leading to some neurogenesis and synaptogenesis. Though 
neurogenesis appears rarely in the injured brain [172], rodent studies have shown that acute 
brain insults initiate proliferation of neural stem cells in the subventricular and subgranular 
zones [171]. Although spontaneous recovery by neurogenesis is limited following brain 
injury, there is an obvious need to develop strategies to improve regenerative processes 
including proliferation of neuronal precursor cells, migration of precursor cells to the injury 
area, differentiation into mature neurons and the re-establishment of connections between 
neurons [2]. While these endogenous responses are evidently not sufficient to fully restore 
neurological function following various brain insults, selective enhancement of some of 
these processes may serve as a useful therapeutic approach.
To date, the relationship between hypothermia and neurogenesis has only been studied by a 
few groups and is far from clear. Studies examining mild hypothermia in cultured neural 
stem cells showed decreased apoptosis, increased nestin-positive cells, and inhibition of 
stem cell differentiation into astrocytes [173], suggesting an overall inductive role for 
hypothermia in neurogenesis. However, the effects of hypothermia on neurogenesis have 
also been shown to vary according to conditions such as brain age, injured vs. non-injured 
state, and the severity or duration of hypothermia. One study in the developing brain showed 
that cooling to 30°C for 21 hours decreased numbers of proliferating cells in the subgranular 
zone of the hippocampus but not in the periventricular zone [174]. Following hypoxic-
ischemic injury, cooling the developing brain to 33°C showed an increase in neural 
progenitor cell differentiation in the striatum, as well as protection of proliferating neural 
stem cells in response to ischemic stimuli [175]. Studies in global cerebral ischemia models 
showed that mild hypothermia increased newborn neurons in the dentate gyrus relative to 
those of normothermic injured animals [176]. Another study involving global cerebral 
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ischemia in adult rats showed that hypothermia had no effect on neurogenesis [177]. This 
latter study employed a similar model of global cerebral ischemia, but used a shorter cooling 
duration (33°C for 45 minutes). The findings in the adult brain suggest that hypothermia 
may only influence neurogenesis within specific time windows, but these exact time 
windows remain poorly defined.
Reports of hypothermia’s effects on endogenous cell genesis in injured relative to uninjured 
brains have been inconsistent. There are conflicting reports as to whether hypothermia 
suppresses stem cell proliferation [174,178] or induces it [173,176]. Some investigators even 
suggest hypothermia may preferentially promote cell differentiation toward neurogenesis 
over gliogenesis [173,175]. Studies also indicate that the effect of hypothermia on 
gliogenesis is dependent upon cooling temperature. Cooling to temperatures lower than 
30°C has been shown to induce apoptosis/necrosis and cell cycle arrest as a result of reduced 
energy supply, thereby suppressing cell proliferation [174,179]. In contrast, mild 
hypothermia has been shown to protect against progenitor cell death [173,178].
Brain injury studies have found that gliogenesis and angiogenesis contributes to brain 
recovery following various insults [171,180]. However, the role of newborn astrocytes and 
vascular cells post insult has not been studied extensively. Astrocytes comprise the largest 
population of cells in the brain [181], and glial scar formation following injury is thought to 
obstruct new neurite outgrowth [182,183]. However, the inhibition of astrocytic activation 
and related downstream processes can exacerbate injury responses including inflammation 
[183]. Mild hypothermia has also been observed to increase angiogenic signals in stroke 
[184], spinal cord injury [185], and traumatic brain injury models [186], but the significance 
of these observations has yet to be clarified.
Although less understood, oligodendrocytes are known to respond to brain injury in a 
manner similar to neurons. Hypothermia has also been shown to attenuate trauma-induced 
oligodendrocyte death, demyelination, and circuit disruption [187]. Hypothermia improved 
survival in primary cultures of mouse oligodendrocyte precursor cells [188], demonstrating 
that cooling can help the prenatal brain retain greater numbers of actively replicating, less-
differentiated oligodendrocyte precursor cells.
Few studies have examined the role of hypothermia on neuronal circuit repair. Repair of 
synaptic connectivity is crucial to functional recovery after brain injury. Deep hypothermia 
(17°C) showed neurite and axonal outgrowth in brain slices [137,189], suggesting that 
cooling may have a restorative effect on cell morphology. Mild hypothermia has also been 
shown to significantly alter hippocampal gene expression to favor synpaptogenesis in rat 
brains after traumatic brain injury. One study identified 133 transcripts altered by brain 
injury whose expression profiles were statistically different between hypothermic and 
normothermic groups. Of the 57 transcripts upregulated by hypothermia, especially 
prominent increases were observed among genes related to synapse organization and 
biogenesis.
While the full effect of cooling in brain repair is still unclear, current research suggests that 
therapeutic hypothermia may have a beneficial role under specific conditions, whether by 
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protecting stem cells, promoting their proliferation and differentiation, increasing growth-
factor signaling, and encouraging recovery of neural circuitry.
5. THERAPEUTIC HYPOTHERMIA AS A MODEL OF NEUROPROTECTION
Although TH is a promising therapeutic starategy shown to improve neurological outcome 
for certain clinical conditions, it is not always practical or feasible to cool many patients 
with acute cerebral injuries. However, TH might also be described as a ‘model of 
neuroprotection’ where therapeutic strategies could be identified, taking into consideration 
some of the benefits of hypothermia without the risks or challenges.
Protective mechanism of hypothermia appears to affect multiple aspects of ischemia 
pathogenesis. Therefore, it may behoove investigators to identify drugs that may also have 
similar multi-faceted properties [2,47]. Representative of such multi-faceted drugs are 
minocycline and fingolimod .
Like TH, minocycline, which is semi-synthetic tetracycline antibiotic, confers robust 
neuroprotective effects through similar mechanisms as cooling. Minocyline has been shown 
to attenuate neuro-inflammation, reduction of the matrix metalloproteinases (MMPs) and 
apoptosis [190–194]. Minocycline is also available in an oral form, and there is already 
abundant clinical experience in terms of dosing and safety. A few small studies of 
minocycline in stroke patients was shown to improve neurological outcome [50,195]. The 
efficacy of minocycline in combination with alteplase (rt-PA) in acute ischemic stroke 
patients is ongoing. An early phase dose-finding trial, the “Minocycline to improve 
Neurological Outcome in Stroke trial” (MINOS) [196,197], showed that intravenous 
minocycline was safe and well tolerated when administrated alone or concurrently with rt-
PA. In addition to these trials, there is an ongoing trial [198] of minocycline plus rt-PA in 
acute ischemic stroke. One clinical trial investigating the efficacy of minocycline in patients 
with cerebral hemorrhage is also on-going[199]. However, the efficacy of minocycline in 
various cerebral injuries requires further investigation in larger phase III clinical trials.
Another representative drug which can provide neuroprotection through multifaceted effects 
is fingolimod. Fingolimod is an immune modulator that non-selectively targets the 
sphingosine-1-phosphate (S1P) receptor, and has been approved for the treatment of 
multiple sclerosis by the US Food and Drug Administration [200]. In brain injury models, 
there appears to be a similar beneficial effect of fingolimod treatment [201–204]. Its 
protective mechanism is thought to be related to the stabilization of the BBB [205], 
inhibition of lymphocyte migration [206] and reduction of neuronal apoptosis with 
upregulation of survival pathways [207]. In ischemic stroke patients, Fu et al. [208,209] 
carried out a series of trials to explore the efficacy of fingolimod. They found that 
fingolimod exhibited neuroprotective effects when combined with rt-PA, and led to 
decreased infarct volume and improved neurological function. Moreover, smaller 
hemorrhage volumes resulted in patients treated with rt-PA plus fingolimod. However, its 
long-term effects are still unclear, and any adverse effects due to immunosuppression or 
cardiac effects need to be clarified. Large-scale trials are warranted in stroke and related 
conditions. With increasing availability of gene profiling technologies, it is possible to 
identify large numbers of genes and changes in those genes in a relatively short period of 
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time. In work by Kobayashi and colleagues [210], rats were subjected to cerebral ischemic 
injury under normothermic, hypothermic or hyperthermic conditions. Brain samples were 
subjected to gene profiling which identified 33 genes that were temperature sensitive. Many 
of these genes and their gene products had been studied in the scientific literature previously, 
and cooling seemed to lead to the suppression of genes, most of which have been described 
as being neurotoxic. However, cooling also led to the upregulation of several cytoprotective 
genes. Interestingly, many of the genes altered by hypothermia were similarly changed by 
preconditioning, an endogenous defense mechanism. Thus, future research may focus on the 
significance of these genes in acute cerebral insults, and whether their modulation represents 
a potential therapeutic target by the development of novel drugs.
However, not all protein and gene changes observed by cooling translate into an instant 
therapeutic target. One example of this is the 70 kD heat shock protein (HSP70), which is 
known as stress related protein [106]. While HSP70 is upregulated in the various acute 
cerebral injuries and is known to protect brain from its injuries [211–213], previous studies 
reported that hypothermia down-regulated its expression [214,215]. Thus, validation of the 
significance of observed changes by hypothermia would be obviously needed.
6. CONCLUSION
Hypothermia has long been known to be a potent neuroprotective intervention that preserves 
tissues and limits injury after various acute cerebral insults. Experimental evidence and 
clinical experience show that induced hypothermia affects nearly every metabolic, molecular 
and cellular event in cell death to promote tissue preservation. The multiple ways therapeutic 
hypothermia affects protection has shown that the goal of neuroprotection requires multi-
target approaches. It may also be possible to extend the therapeutic window for other 
neuroprotective treatments by hypothermia, and combination therapies with neuroprotective 
drugs such as anti-inflammatory, anti-apoptotic and thrombolytic agents. This effect of 
hypothermia may lead to the re-examination of the many failed neuroprotectant drugs at the 
clinical level, since many drugs may not have been studied under optimal conditions.
In spite of the robust protective effect demonstrated in the laboratory, there are still clinical 
obstacles to overcome, including effective cooling in humans and prevention of harmful 
side-effects. There is also a need to develop more sophisticated translational research tools 
in the lab. Animal models and the method of cooling used in the laboratory are quite 
different from those employed clinically. Thus, an effort to simulate the clinical condition 
more precisely might provide solutions for better and wider application of TH in patients.
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Figure. Phase specific effect of hypothermia therapy.
Diagram shows the different phases of neurological insults and the corresponding 
pathological processes that occur during that phase. Therapeutic cooling has been shown to 
each of these phases by influencing the pathways described.
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Table 1.
Classificartion of pharmacological agents that can induce hypothermia
Class Representative drug target of pharmacological action
Cannabioid (CB) System
[30–33]
WIN5512–2 CB1 agonist
HU-210 CB1 agonist
TAK-937 CB1/CB2 agonist
TRPV-1 Receptor Capsaicin thermoregulator in peripheral nerves and hypothalamus
Opioid Receptors U50, 488H κ-opioid agonist
SNC-80 δ-opioid agonist
Neurotensin NT69L neurotensin analog
JMV449 neurotensin analog
Thyroxine Derivatives T0AM Trace amine-associated receptor
T1AM Trace amine-associated receptor
Dopamine Receptor Activators Lisutide D2 dopamine receptor agonist
Talipexole D2 dopamine receptor agonist
Gasseous Hypothermia Xenone, Helium Unknown
Adenosine and Adenine Nucleotides AMP A1 receptor agonist
ATP Unknown
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Table 2.
Summary of therapeutic strategies and drugs tested in combination with hypothermia therapy.
Concept of therapeutic strategy phamacological target Specified Treatment
Reducing excitotoxicitty
NMDA receptor antagonist
MK801 [38–40]
Selfotel [41, 42]
Mg2+　[43, 44]
Anti-inflammation immunosuppressive Tacrolimus [46]
Antibiotics Minocycline [47, 48]
Anti-oxidative stress
free radical scavenger
Edaravone [49]
Mannitol
Increase blood supply Vasodilator Statin
Angiogenesis G-CSF
Multiple protection antidiabetics glibenclamide [35–37]
trophic factors
Insulin-like growth factor (IGF-1)
Brain derived neurotrophic factor (BDNF)
other Albumin
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Table 3.
Summary of the Therapeutic Efficacy of Hypothermia for Neurological Injury
Pathological type of acute brain injury
Current status of therapeutic hypothermia
pre-clinical clinical studies
Cardiac Arrest protectie [17,19] beneficial [3,4]
neonatal hypoxic-ischemic encephalopathy (HIE) protective [51] beneficial [5,7]
Ischemic stroke transient: protective [17,22]
controversial [14, 15, 19]
permanent: controversial
Intra cerebral hemmorhage (ICH) controversial [55–60] controversial [61–64]
Subarachnoid hemorrhage (SAH) protective [65–67] controversial [68–70]
Traumatic brain injury (TBI) protective [73–78] controversial [79–86]
Spinal cord injury (SCI) protective [90–96] controversial [87,88]
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